Guest writer Lindsay Kelly describes the shift she experienced in terms of the resentment she'd felt about her husband's ...

A committee in the EU recommended that tolebrutinib, to be sold as Cenrifki, be approved for people with SPMS with no relapses for two years.

Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...

Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...

Columnist Ben Hofmeister reflects on the feelings of guilt that surfaced after writing that his present vehicle no longer met his needs.

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

Scientists studying animals at high altitudes discovered a previously unknown mechanism that is key for regulating myelin ...

Columnist Desiree Lama is reconnecting with her love of plants and being outside after starting an outdoor garden at her new ...

The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...

Guest writer Kevin Byrne explains "Garage Dayz," his ambitious cycling project dedicated to fellow members of the MS ...

Guest columnist Lindsay Kelly says that receiving her husband Rhead's MS diagnosis gave her a helpful framework for ...

A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...